elranatamab will boost the level or impact of ergotamine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of. Elranatamab results in cytokine launch syndrome (CRS) that may suppress exercise of CYP enzymes, leading to increased exposure of CYP substrates.Our website employs cookies to gather valuable info that allows